FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947488997> ?p ?o ?g. }

• W2947488997 endingPage "231" @default.
• W2947488997 startingPage "223" @default.
• W2947488997 abstract "Background Type II endoleaks (T2ELs) are common following endovascular repair of abdominal aortic aneurysms (EVAR). Embolization with ethylene vinyl alcohol copolymer (Onyx) may present an effective treatment alternative for T2ELs. Due to limited data supporting its use, we sought to analyze outcomes of Onyx embolization for T2ELs. Methods Retrospective review of consecutive patients treated for T2ELs utilizing Onyx embolization agent from 2009–2018. All pre- and post-Onyx intervention CT scans were analyzed for diameter and volume changes with 3D reconstruction software. The primary outcomes were change in maximum AAA diameter and volume. Secondary outcomes included additional interventions, rupture, and mortality. A subset analysis was performed with patients with isolated T2ELs (no other types of endoleaks present). Results We identified 85 patients (73 males, mean age 77.6 ± 7.6 years) who underwent 112 Onyx interventions. Average time to first Onyx intervention after index EVAR was 3.3 ± 2.6 years and average sac growth was 6.3 ± 6.7 mm. Patients underwent mean 1.3 Onyx interventions using a mean of 4.9 ± 4.7 ml for treatment. Three complications occurred (Onyx extravasation, colon ischemia, and access site hematoma). Mean follow-up was 2.5 ± 2.1 years after initial Onyx treatment. At the most recent follow-up, sac diameter stabilization was seen in 47% and reduction >5 mm was seen in 19%. Sac growth of >5 mm was seen in 34% of patients following the first Onyx intervention. In our subset of isolated T2EL, 72% had sac stabilization or reduction >5 mm. Four patients experienced a ruptured aneurysm (3 had active type 1 endoleaks). Rupture-free survival was 95% at 5 years, and overall survival was 54% at 5 years. Notably, increasing Onyx interventions were not associated with sac stabilization or reduction (OR 0.6, P = 0.1). On multivariable analysis, AAA sac diameter stabilization or reduction was independently associated with BMI >30 kg/m2 (OR 4.2, P = 0.01) and having only 1 Onyx intervention (OR 3.8, P = 0.02). Conclusions Onyx for embolization of T2ELs resulted in AAA sac diameter stabilization or reduction in 66% of patients, and up to 72% in isolated T2ELs. Further, increasing Onyx interventions were not associated with either aneurysm sac stabilization or reduction. Given its similar outcomes to other embolization strategies in the literature, Onyx embolization for management of T2ELs needs to be judiciously considered, particularly for T2ELs persisting after an initial Onyx embolization intervention. Type II endoleaks (T2ELs) are common following endovascular repair of abdominal aortic aneurysms (EVAR). Embolization with ethylene vinyl alcohol copolymer (Onyx) may present an effective treatment alternative for T2ELs. Due to limited data supporting its use, we sought to analyze outcomes of Onyx embolization for T2ELs. Retrospective review of consecutive patients treated for T2ELs utilizing Onyx embolization agent from 2009–2018. All pre- and post-Onyx intervention CT scans were analyzed for diameter and volume changes with 3D reconstruction software. The primary outcomes were change in maximum AAA diameter and volume. Secondary outcomes included additional interventions, rupture, and mortality. A subset analysis was performed with patients with isolated T2ELs (no other types of endoleaks present). We identified 85 patients (73 males, mean age 77.6 ± 7.6 years) who underwent 112 Onyx interventions. Average time to first Onyx intervention after index EVAR was 3.3 ± 2.6 years and average sac growth was 6.3 ± 6.7 mm. Patients underwent mean 1.3 Onyx interventions using a mean of 4.9 ± 4.7 ml for treatment. Three complications occurred (Onyx extravasation, colon ischemia, and access site hematoma). Mean follow-up was 2.5 ± 2.1 years after initial Onyx treatment. At the most recent follow-up, sac diameter stabilization was seen in 47% and reduction >5 mm was seen in 19%. Sac growth of >5 mm was seen in 34% of patients following the first Onyx intervention. In our subset of isolated T2EL, 72% had sac stabilization or reduction >5 mm. Four patients experienced a ruptured aneurysm (3 had active type 1 endoleaks). Rupture-free survival was 95% at 5 years, and overall survival was 54% at 5 years. Notably, increasing Onyx interventions were not associated with sac stabilization or reduction (OR 0.6, P = 0.1). On multivariable analysis, AAA sac diameter stabilization or reduction was independently associated with BMI >30 kg/m2 (OR 4.2, P = 0.01) and having only 1 Onyx intervention (OR 3.8, P = 0.02). Onyx for embolization of T2ELs resulted in AAA sac diameter stabilization or reduction in 66% of patients, and up to 72% in isolated T2ELs. Further, increasing Onyx interventions were not associated with either aneurysm sac stabilization or reduction. Given its similar outcomes to other embolization strategies in the literature, Onyx embolization for management of T2ELs needs to be judiciously considered, particularly for T2ELs persisting after an initial Onyx embolization intervention." @default.
• W2947488997 created "2019-06-07" @default.
• W2947488997 creator A5005427596 @default.
• W2947488997 creator A5010267073 @default.
• W2947488997 creator A5018047889 @default.
• W2947488997 creator A5025348383 @default.
• W2947488997 creator A5028429089 @default.
• W2947488997 creator A5029552702 @default.
• W2947488997 creator A5043875322 @default.
• W2947488997 creator A5053378731 @default.
• W2947488997 creator A5055044637 @default.
• W2947488997 creator A5057541046 @default.
• W2947488997 creator A5065997886 @default.
• W2947488997 creator A5074674827 @default.
• W2947488997 creator A5080224993 @default.
• W2947488997 date "2020-08-01" @default.
• W2947488997 modified "2023-09-23" @default.
• W2947488997 title "Outcomes of Onyx® Embolization of Type II Endoleaks After Endovascular Repair of Abdominal Aortic Aneurysms" @default.
• W2947488997 cites W135841707 @default.
• W2947488997 cites W1976509795 @default.
• W2947488997 cites W1982812259 @default.
• W2947488997 cites W2012533421 @default.
• W2947488997 cites W2013462858 @default.
• W2947488997 cites W2021942359 @default.
• W2947488997 cites W2067821794 @default.
• W2947488997 cites W2069583088 @default.
• W2947488997 cites W2090099381 @default.
• W2947488997 cites W2145621890 @default.
• W2947488997 cites W2148732809 @default.
• W2947488997 cites W2323254496 @default.
• W2947488997 cites W2586593502 @default.
• W2947488997 cites W2811362723 @default.
• W2947488997 cites W2945135762 @default.
• W2947488997 cites W2790531008 @default.
• W2947488997 doi "https://doi.org/10.1016/j.avsg.2020.02.013" @default.
• W2947488997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32173471" @default.
• W2947488997 hasPublicationYear "2020" @default.
• W2947488997 type Work @default.
• W2947488997 sameAs 2947488997 @default.
• W2947488997 citedByCount "12" @default.
• W2947488997 countsByYear W29474889972020 @default.
• W2947488997 countsByYear W29474889972021 @default.
• W2947488997 countsByYear W29474889972022 @default.
• W2947488997 countsByYear W29474889972023 @default.
• W2947488997 crossrefType "journal-article" @default.
• W2947488997 hasAuthorship W2947488997A5005427596 @default.
• W2947488997 hasAuthorship W2947488997A5010267073 @default.
• W2947488997 hasAuthorship W2947488997A5018047889 @default.
• W2947488997 hasAuthorship W2947488997A5025348383 @default.
• W2947488997 hasAuthorship W2947488997A5028429089 @default.
• W2947488997 hasAuthorship W2947488997A5029552702 @default.
• W2947488997 hasAuthorship W2947488997A5043875322 @default.
• W2947488997 hasAuthorship W2947488997A5053378731 @default.
• W2947488997 hasAuthorship W2947488997A5055044637 @default.
• W2947488997 hasAuthorship W2947488997A5057541046 @default.
• W2947488997 hasAuthorship W2947488997A5065997886 @default.
• W2947488997 hasAuthorship W2947488997A5074674827 @default.
• W2947488997 hasAuthorship W2947488997A5080224993 @default.
• W2947488997 hasConcept C126838900 @default.
• W2947488997 hasConcept C141071460 @default.
• W2947488997 hasConcept C167135981 @default.
• W2947488997 hasConcept C2776035437 @default.
• W2947488997 hasConcept C2776098176 @default.
• W2947488997 hasConcept C2777323849 @default.
• W2947488997 hasConcept C2779662492 @default.
• W2947488997 hasConcept C2779993416 @default.
• W2947488997 hasConcept C2994150672 @default.
• W2947488997 hasConcept C71924100 @default.
• W2947488997 hasConceptScore W2947488997C126838900 @default.
• W2947488997 hasConceptScore W2947488997C141071460 @default.
• W2947488997 hasConceptScore W2947488997C167135981 @default.
• W2947488997 hasConceptScore W2947488997C2776035437 @default.
• W2947488997 hasConceptScore W2947488997C2776098176 @default.
• W2947488997 hasConceptScore W2947488997C2777323849 @default.
• W2947488997 hasConceptScore W2947488997C2779662492 @default.
• W2947488997 hasConceptScore W2947488997C2779993416 @default.
• W2947488997 hasConceptScore W2947488997C2994150672 @default.
• W2947488997 hasConceptScore W2947488997C71924100 @default.
• W2947488997 hasLocation W29474889971 @default.
• W2947488997 hasLocation W29474889972 @default.
• W2947488997 hasOpenAccess W2947488997 @default.
• W2947488997 hasPrimaryLocation W29474889971 @default.
• W2947488997 hasRelatedWork W1550671225 @default.
• W2947488997 hasRelatedWork W1992069132 @default.
• W2947488997 hasRelatedWork W2088352857 @default.
• W2947488997 hasRelatedWork W2337053829 @default.
• W2947488997 hasRelatedWork W2355257259 @default.
• W2947488997 hasRelatedWork W2463544427 @default.
• W2947488997 hasRelatedWork W2530620897 @default.
• W2947488997 hasRelatedWork W3163115693 @default.
• W2947488997 hasRelatedWork W4284966660 @default.
• W2947488997 hasRelatedWork W4362522233 @default.
• W2947488997 hasVolume "67" @default.
• W2947488997 isParatext "false" @default.
• W2947488997 isRetracted "false" @default.
• W2947488997 magId "2947488997" @default.
• W2947488997 workType "article" @default.